Urogen Pharma [URGN] vs Zymeworks [ZYME] Detailed Stock Comparison
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Urogen Pharma Ltd. wins in 7 metrics, Zymeworks Inc. wins in 11 metrics, with 0 ties. Zymeworks Inc. appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Urogen Pharma Ltd. | Zymeworks Inc. | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -7.62 | 3.79 | Zymeworks Inc. |
| Price-to-Book Ratio | -11.34 | 7.32 | Zymeworks Inc. |
| Debt-to-Equity Ratio | -1.23 | 6.80 | Zymeworks Inc. |
| PEG Ratio | 0.23 | 0.05 | Zymeworks Inc. |
| EV/EBITDA | -9.86 | -20.40 | Urogen Pharma Ltd. |
| Profit Margin (TTM) | -139.81% | -76.56% | Zymeworks Inc. |
| Operating Margin (TTM) | -50.52% | -1,755.55% | Urogen Pharma Ltd. |
| Return on Equity | 145.53% | -26.72% | Urogen Pharma Ltd. |
| Return on Assets (TTM) | -32.10% | -14.29% | Zymeworks Inc. |
| Free Cash Flow (TTM) | $-162.73M | $-35.36M | Zymeworks Inc. |
| 1-Year Return | 563.44% | 119.86% | Urogen Pharma Ltd. |
| Price-to-Sales Ratio (TTM) | 11.10 | 18.46 | Urogen Pharma Ltd. |
| Enterprise Value | $1.23B | $1.73B | Zymeworks Inc. |
| EV/Revenue Ratio | 11.19 | 16.33 | Urogen Pharma Ltd. |
| Gross Profit Margin (TTM) | 91.31% | N/A | N/A |
| Revenue per Share (TTM) | $2 | $1 | Urogen Pharma Ltd. |
| Earnings per Share (Diluted) | $-3.19 | $-1.08 | Zymeworks Inc. |
| Beta (Stock Volatility) | 1.44 | 1.20 | Zymeworks Inc. |
| Short % of Float | 17.40% | 8.16% | Zymeworks Inc. |
Urogen Pharma Ltd. vs Zymeworks Inc. Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Urogen Pharma Ltd. | 0.17% | -9.38% | 14.13% | 41.23% | 9.16% | 17.04% |
| Zymeworks Inc. | 1.00% | -1.77% | -9.07% | -0.41% | -7.13% | -8.53% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Urogen Pharma Ltd. | 563.44% | 188.81% | 56.45% | 100.93% | 100.93% | 100.93% |
| Zymeworks Inc. | 119.86% | 189.85% | -20.78% | 93.31% | 93.31% | 93.31% |
Performance & Financial Health Analysis: Urogen Pharma Ltd. vs Zymeworks Inc.
| Metric | URGN | ZYME |
|---|---|---|
| Market Information | ||
| Market Cap | $1.18B | $1.96B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 913,553 | 626,460 |
| 90 Day Avg. Volume | 733,814 | 729,503 |
| Last Close | $26.58 | $24.35 |
| 52 Week Range | $4.71 - $32.37 | $11.51 - $29.75 |
| % from 52W High | -17.87% | -18.15% |
| All-Time High | $69.57 (May 21, 2018) | $59.03 (Jan 11, 2021) |
| % from All-Time High | -61.79% | -58.75% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.54% | -0.92% |
| Quarterly Earnings Growth | 0.54% | -0.92% |
| Financial Health | ||
| Profit Margin (TTM) | -1.40% | -0.77% |
| Operating Margin (TTM) | -0.51% | -17.56% |
| Return on Equity (TTM) | 1.46% | -0.27% |
| Debt to Equity (MRQ) | -1.23 | 6.80 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $-2.18 | $3.60 |
| Cash per Share (MRQ) | $2.47 | $3.10 |
| Operating Cash Flow (TTM) | $-162,444,000 | $-33,005,000 |
| Levered Free Cash Flow (TTM) | $-99,423,000 | $-12,959,125 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Urogen Pharma Ltd. vs Zymeworks Inc.
| Metric | URGN (Apr 24, 2026) | ZYME (Apr 13, 2026) |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -7.62 | 3.79 |
| Forward P/E | 24.07 | 33.43 |
| PEG Ratio | 0.23 | 0.05 |
| Price to Sales (TTM) | 11.10 | 18.46 |
| Price to Book (MRQ) | -11.34 | 7.32 |
| Market Capitalization | ||
| Market Capitalization | $1.18B | $1.96B |
| Enterprise Value | $1.23B | $1.73B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 11.19 | 16.33 |
| Enterprise to EBITDA | -9.86 | -20.40 |
| Risk & Other Metrics | ||
| Beta | 1.44 | 1.20 |
| Book Value per Share (MRQ) | $-2.18 | $3.60 |
Financial Statements Comparison: Urogen Pharma Ltd. vs Zymeworks Inc.
Financial Metrics
Loading Financial Charts...
Revenue
Operating Margin
Profit Margin
Long Term Debt
Income Flow Analysis
Financial Statements Comparison
Income Statement
| Metric | URGN (2025) | ZYME (2025) |
|---|---|---|
| Revenue/Sales | 109.79M | 105.97M |
| Cost of Goods Sold | 12.45M | N/A |
| COGS % of Revenue | 11.3% | 0.0% |
| Gross Profit | 97.34M | N/A |
| Gross Margin | 88.7% | 0.0% |
| Research & Development | 67.11M | 137.00M |
| Operating Income (EBIT) | -124.86M | -92.54M |
| Operating Margin | -113.7% | -87.3% |
| EBITDA | -135.66M | -80.82M |
| EBITDA Margin | -123.6% | -76.3% |
| Pre-Tax Income | -153.42M | -79.75M |
| Pre-Tax Income % of Revenue | -139.7% | -75.3% |
| Income Tax | 78,000 | 1.38M |
| Income Tax % of Revenue | 0.1% | 1.3% |
| Net Income (Profit) | -153.49M | -81.13M |
| Profit Margin | -139.8% | -76.6% |
Balance Sheet & Liquidity Metrics
| Metric | URGN (2025) | ZYME (2025) |
|---|---|---|
| Cash & Equivalents | 110.75M | 41.16M |
| Total Current Assets | 186.02M | 248.77M |
| Total Current Assets % of Revenue | 169.4% | 234.8% |
| Total Current Liabilities | 46.42M | 42.32M |
| Total Current Liabilities % of Revenue | 42.3% | 39.9% |
| Long-Term Debt | 128.33M | 14.80M |
| Long-Term Debt % of Revenue | 116.9% | 14.0% |
| Total Shareholders Equity | -105.47M | 268.50M |
| Retained Earnings | -959.72M | -953.16M |
| Retained Earnings % of Revenue | -874.2% | -899.5% |
| Property, Plant & Equipment | 9.64M | 29.56M |
Cash Flow Statement Comparison
| Metric | URGN (2025) | ZYME (2025) |
|---|---|---|
| Operating Cash Flow | -160.55M | -40.00M |
| Operating Cash Flow % of Revenue | -146.2% | -37.7% |
| Capital Expenditures | -289,000 | -1.52M |
| Free Cash Flow | -162.73M | -35.36M |
| FCF Margin | -148.2% | -33.4% |
| Debt Repayment | -1.86M | N/A |
| Common Stock Repurchase | N/A | -41.70M |
Short Interest & Institutional Ownership Analysis
| Metric | URGN | ZYME |
|---|---|---|
| Shares Short | 8.35M | 4.08M |
| Short Ratio | 9.29 | 5.42 |
| Short % of Float | 17.40% | 8.16% |
| Shares Outstanding | 48.35M | 75.19M |
| Float Shares | 38.66M | 72.80M |
| % Held by Insiders | 3.75% | 1.26% |
| % Held by Institutions | 99.35% | 98.45% |
| % Held by Public | -3.10% | 0.29% |
Dividend Analysis & Yield Comparison: Urogen Pharma Ltd. vs Zymeworks Inc.
| Metric | URGN | ZYME |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |